Browse by Clinical Topic:

Featured CME/CE Content:
neuroscienceCME Editors' Picks:

Ask the Expert Q&A
Technologies to Advance the Treatment of Alzheimer's Disease

neuroscienceCME Webcast

Premiere Date: Wednesday, September 4, 2013

This activity offers CE credit for:

  1. Physicians (CME)
  2. Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date:
Thursday, September 4, 2014
Note: Credit Is No Longer Available


Gary W. Small, MDGary W. Small, MD 
Professor of Psychiatry & Biobehavioral Sciences
Parlow-Solomon Professor on Aging
David Geffen School of Medicine
University of California, Los Angeles
Los Angeles, CA

Statement of Need

CME Outfitters and the American Association for Geriatric Psychiatry (AAGP) conducted a symposium entitled Technologies to Advance the Treatment of Alzheimer’s Disease at the AAGP annual meeting on March 15, 2013. The activity was attended by geriatric psychiatrists and psychiatrists with an interest in Alzheimer’s disease and focused on: 1) advances in the technology of biomarkers to evaluate and diagnose Alzheimer’s disease and 2) a new diagnostic language to describe the various dimensions of Alzheimer’s disease.

This live, interactive symposium was captured on video and is available as a certified activity at and Because the opportunity to engage and connect with faculty is critical to the translation of the data, a live Q & A has been scheduled to Ask the Expert on Wednesday, September 4, 2013. During this activity, you will be able to ask questions, discuss your clinical case successes and challenges; and gain insight and practice pearls from Gary W. Small, MD. Please register in advance for this live Q & A session. It is an activity that you don’t want to miss!

  • Dubois B, Feldman HH, Jacova C, et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol. 2010;9(11):1118-1127. PMID: 20934914.
  • Teipel SJ, Sabri O, Grothe M, et al. Perspectives for multimodal neurochemical and imaging biomarkers in Alzheimer's disease. J Alzheimers Dis. 2013;33(0):S329-S347. PMID: 22735677.
  • Activity Goal

    The goal of this educational intervention is to educate clinicians about the latest biomarker technologies for Alzheimer’s disease (AD), the new diagnostic language to support and describe the spectrum of AD, and the need to discuss the effects of an AD diagnosis with patients and families.

    Learning Objectives

    At the end of this CE activity, participants should be able to:

    • Implement the latest biomarker technologies, such as brain imaging and cerebrospinal fluid analysis, when appropriate, in the management of patients with Alzheimer’s disease.
    • Incorporate the new Alzheimer’s disease diagnostic criteria, when appropriate, into clinical practice.
    • Enumerate three discussion points that can guide a discussion with patients and their families about the implications of Alzheimer’s disease.

    Financial Support

    Provided by the American Association for Geriatric Psychiatry. This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit

    Target Audience

    Physicians and other health care professionals who work with older adults.

    Credit Information

    CME Credit (Physicians):
    The American Association for Geriatric Psychiatry (AAGP) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    The American Association for Geriatric Psychiatry (AAGP) designates this enduring material for a maximum of .5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Post-tests, credit request forms, and activity evaluations must be completed online at (requires free account activation), and participants can print their certificate or statement of credit immediately (80% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit

    Policy on privacy and confidentiality: Click here to view AAGP’s privacy and confidentiality policy.

    Copyright: The American Association for Geriatric Psychiatry owns the copyright for this material or has obtained permission to distribute this material from all speakers.

    Disclosure of Relevant Financial Relationships with Commercial Interests

    American Association for Geriatric Psychiatry (AAGP) and CME Outfitters, LLC, adhere to the ACCME Standards regarding commercial support of continuing medical education. It is the policy of AAGP and CME Outfitters, LLC, that the faculty and planning committee disclose real or apparent conflicts of interest relating to the topics of this educational activity, that relevant conflict(s) of interest are resolved, and also that speakers will disclose any unlabeled/unapproved use of drug(s) or device(s) during their presentation.

    A conflict of interest is created when individuals in a position to control the content of CME have a relevant financial relationship with a commercial interest which therefore may bias his/her opinion and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks or other financial benefits.

    AAGP and CME Outfitters will identify, review, and resolve all conflicts of interest that speakers, authors or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

    Relevant financial relationships exist between the following individuals and commercial interests:

    Dr. Small has disclosed that he serves as a consultant to Eli Lilly and Company; Janssen Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and Pfizer Inc.. He serves on the speaker's bureau of Novartis Pharmaceuticals Corporation.

    Christine M. deVries (AAGP staff - planning committee) has nothing to disclose

    Marjorie Vanderbilt (AAGP staff - planning committee) has nothing to disclose

    Daniel Bateman, MD (content/peer reviewer) has nothing to disclose.

    David Beck, MD (content/peer reviewer) has nothing to disclose.

    Tatyana P. Shteinlukht, MD, PhD (content/peer reviewer) has nothing to disclose.

    Robert Kennedy (planning committee) has nothing to disclose.

    Joy Bartnett Leffler, MLA, NASW, CSE (planning committee) has nothing to disclose.

    Sandra Haas Binford, MAEd (planning committee) has nothing to disclose.

    Sharon Tordoff, CCMEP (planning committee) has nothing to disclose.

    Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

    AAGP, CME Outfitters, LLC, the faculty, and Lilly USA, LLC do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

    Questions about this activity? Call us at 877.CME.PROS (877.263.7767).


    Home      |      Register/Log In      |      Activities      |      Communities of Practice      |      About      |      Download